Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report

ANNAPAOLA MARINIELLO1, ELEONORA GHISONI2,3, LUISELLA RIGHI1, ANNAMARIA CATINO4, RITA CHIARI5, ALESSANDRO DEL CONTE6, FAUSTO BARBIERI7, FABIANA CECERE8, ALAIN GELIBTER9, MATTEO GIAJLEVRA10, HECTOR SOTO PARRA11, CLIZIA ZICHI1, MASSIMO DI MAIO12, GIORGIO VALABREGA2,3 and SILVIA NOVELLO1

1Department of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy; 2Department of Oncology, University of Torino, Turin, Italy; 3Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; 4Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy; 5Department of Medical Oncology, University of Perugia at Santa Maria della Misericordia Hospital, Perugia, Italy; 6Centro di Riferimento Oncologico (CRO) - IRCCS, Oncology Unit, Pordenone, Italy; 7Department of Oncology and Hematology, University-Hospital of Modena and Reggio Emilia, Modena, Italy; 8Careggi University Hospital, Medical Oncology Unit, Department of Oncology, Florence, Italy; 9Sapienza University of Rome at Policlinico Umberto I, Oncology Unit, Rome, Italy; 10CHU Grenoble Alpes, Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, Grenoble, France; 11AOU Policlinico Vittorio Emanuele, Medical Oncology, Catania, Italy; 12Department of Oncology, University of Torino at Mauriziano Umberto I Hospital, Turin, Italy

Abstract. Background/Aim: Double diagnosis of lung cancer (LC) and ovarian cancer (OC) is rare. Here, we describe patients with synchronous/metachronous LC and OC to identify common clinical and pathological patterns. Patients and Methods: Clinical, pathological and molecular data of patients diagnosed and treated at 30 European Institutions from 2008 to 2018 were retrieved and analysed. Whenever tissue was available, centralized pathology revision was performed. Results: A total of 19 cases were found; one was excluded at pathology revision. Most LCs were adenocarcinomas (15/18) and most OCs were high-grade serous (15/18) carcinomas. Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. One patient with a germline-BRCA1 mutation received olaparib, resulting in a durable response of both malignancies. Median overall survival was 33 months. Conclusion: In our series, most synchronous/metachronous LCs and OCs showed genetic alterations. Further analyses with wide NGS panel could shed light on the biological mechanisms driving their occurrence.

Over the past few decades, lung cancer (LC) diagnoses and mortality have progressively increased in the female population. Non-small cell LC (NSCLC) accounts for about 85% of all LC cases and represents the first cause of cancer death and the third most common cancer in women living in developed countries (1). In the same context, ovarian cancer (OC) is the eighth malignancy for incidence and the fifth for mortality (2).

In advanced stages, despite multidisciplinary management and treatment combining surgery, chemotherapy and targeted therapy, prognosis remains poor for both malignancies (2). Epidemiological studies and – more recently – molecular testing have revealed that in the female population NSCLC could be a biologically distinct entity, due to shared clinical and molecular features associated with better prognosis (3). Women affected by NSCLC show a higher incidence of mutations in the epidermal growth factor receptor (EGFR) gene, irrespective from being more often never-smokers. Moreover, whenever these mutations are present, patients receiving targeted therapy with the highly effective tyrosine-kinase inhibitors (TKIs) can achieve a longer life expectancy than the one traditionally obtained with chemotherapy (4).

This article is freely accessible online.

Correspondence to: Dr. Giorgio Valabrega, Department of Oncology, University of Torino at FPO-IRCCS Candiolo Cancer Institute, Strada Provinciale 142, km 3.96, 10100 Candiolo (TO), Italy. Tel: +39 0119933628, e-mail: giorgio.valabrega@unito.it

Key Words: Lung cancer, ovarian cancer, women, homologous recombination deficiency, immunohistochemistry.
In the OC scenario, the availability of DNA sequencing technologies had similar implications: the detection of impairments in genes involved in homologous recombination repair of DNA breaks (Homologous Recombination Deficiency, HRD) has identified a subset of patients with high-grade serous OCs who most likely benefit from treatment with poly(ADP-ribose) polymerase inhibitors (PARPi). Germline or somatic loss-of-function mutations in the BRCA1 or BRCA2 genes are the most common aberrations in HRD. However, other genomic or post-transcriptional events can be responsible for HRD. As reported by the Cancer Genome Atlas, almost half of the high-grade serous OC exhibits HRD. On the other hand, even though rare, cases of HRD have been described also in LC (7).

Despite the increasing incidence of LC, association with OC is rare and, so far, no literature data are available on this topic. The aim of this report was to describe a series of patients with synchronous or metachronous LC and OC and to identify common clinical and pathological patterns.

Patients and Methods

In this descriptive case series, we retrospectively retrieved the medical charts of patients referred to 30 Oncological Institutes in Europe (Italy, France, Slovenia), from 2008 to 2018.

When patients with history of LC and OC were found, detailed medical history was recorded including the following pathological features and clinical outcomes: i) age at first cancer diagnosis; ii) family history of cancer, smoking habits and hormonal status; iii) morphological features of LC and OC including tumor histotype, grade and stage (according to 8th TNM Edition for LC and to the International Federation of Gynecology and Obstetrics (FIGO) for OC; iv) timing and types of either local and systemic treatments received as well as of data regarding treatment initiation and progression; v) survival information. Median overall survival was calculated from the date of diagnosis of the first malignancy to the date of death or date of last follow-up. Whenever tested, genetic alterations, including germline BRCA (gBRCA) mutations in OC, were also reported.

LC and OC were considered synchronous, when the time interval between disease onsets was shorter than 3 months, whereas for metachronous we included all the cases of LC and OC that occurred within a time frame longer than 3 months.

Concerning pathology examination, centralized pathology revision on cytological or histological formalin fixed paraffin embedded tumor tissue (FFPE) was performed at the San Luigi Gonzaga Hospital, where an immunohistochemistry (IHC) marker panel including TTF-1 and PAX-8 was carried out when necessary. In ambiguous cases, a broader panel including p40, CK-7, WT1, CA125, Calretinin, EMA, CEA, CgA, Vimentin, Napsin-A was performed.

Results

As of May 2018, across the 30 Institutes inquired, we retrieved 19 cases of synchronous/metachronous LC and OC in the last 10 years. One patient was excluded, since centralized pathology revision revealed that the lung lesions were actually metastases from OC. Thus, 18 patients were considered eligible for final data analysis. Details of patients' characteristics are reported in Table I.

In the majority of cases (12/18), LC and OC were metachronous, with a median time interval between diagnoses of 6.5 years (range=7 months - 9 years). In the 70.6% of cases, OC preceded LC onset.

As for medical history, median age at diagnosis of the first malignancy was 62 years (range=37-79 years); the majority of patients (61.1%) were never-smokers and 38% had a family history of cancer. Interestingly, five patients (27.7%) were diagnosed with a third or fourth malignancy during their lifetime (1 case of breast cancer, 1 case of lymphoma and colon cancer, 1 case of small bowel cancer, 1 case of breast and kidney cancer and 1 case of medullary thyroid carcinoma).

In most cases, LC was diagnosed at an early or locally advanced stage (33.3% for stage I-IIb and 33.3% stage IIIA), 22.2% cases were metastatic. For two patients, LC staging data were missing. Conversely, at the time of diagnosis, OC cases were predominantly at advanced stage (50% III-IV).

Regarding pathology data, all of the LC diagnoses were performed on the primary tumor lesion. In three cases biopsy tissue consisted of a cytological specimen from broncho-alveolar lavage, in four cases of a cyto-histological specimen from fine (18 Gauge) needle aspiration, in one case of a histological sample from pleural biopsy and one case is unknown. In the remaining nine cases, irrespective of the initial biopsy modality, LC diagnosis was confirmed on surgical specimens. In all of the OC cases, diagnosis was confirmed on surgical specimens. Paired specimens of both primary tumors were available in seven cases.

Regarding histology, 83.3% of LC were adenocarcinoma and 83.3% of OC were high-grade serous carcinoma.

Twelve patients underwent molecular screening for LC oncogene drivers. Of them, 58.3% showed oncogene-addicted lung disease: four cases were EGFR mutant, one B-RAF-V600 mutant and two had EMLA4-ALK rearrangement. Testing for gBRCA status was performed in seven cases: three had mutations (2 BRCA2 and 1 BRCA1), two were wild-type and two carried variants of unknown significance (VUS). Remarkably, one synchronous case of lung and ovarian carcinoma presented both a BRCA-VUS and a B-RAF-V600 mutation at the lung site.

As for treatment, consistent with disease stage at diagnosis, most cases of OC underwent primary de-bulking surgery as frontline therapy (14/18, 77.7%), whereas for LC, lobectomy was performed in eight cases (44.4%). Of the remaining LC cases, four were treated with platinum-based chemotherapy, four received a TKI and two chemoradiotherapy. Regarding OC, all patients received platinum-based chemotherapy, either in adjuvant or first-line setting.

Remarkably, one patient with synchronous advanced
ovarian and lung adenocarcinoma (both in stage IIIA at diagnosis and radically resected) carrying a germline BRCA1 mutation had a durable partial response of both cancers following olaparib treatment for relapse. Ovarian cancer relapse was diagnosed with computed tomography (CT) and positron emission tomography (PET) where increased metabolic activity was detected in interaortocaval and lombo-aortic lymph nodes, along with an increase in CA-125 levels; lung cancer relapse was diagnosed as increased metabolic activity in mediastinal and supraclavicular lymph nodes, with an increase in the levels of CEA and CA 19.9 markers.

At the time of data analysis, after a median follow-up of 6.8 years, median overall survival was 33 months (95% confidence interval (IC)=1.98-55.5)) and 11 patients are still alive (Figure 1).

Two examples of the pathological revisions performed in this study are provided in Figures 2 and 3.

**Discussion**

In this report, we showed that patients who develop double LC and OC primaries share common clinical and pathological features. Notably, in most cases either LC or OC had an underlying molecular alteration. Across the patients who underwent molecular testing for LC, 58.3% showed oncogene-addicted disease. Similarly, of the seven cases tested for BRCA, five showed abnormalities. Moreover, even in cases carrying an unknown variant or were negative for a BRCA mutation, individual history of other associated malignancies or a family history of cancer were observed (2/4 cases and 3/5 cases, respectively).

HRD has been described also in LC, but the overall incidence of germline BRCA mutations in NSCLC is unknown. Among the little available evidence, an interesting perspective is provided by a small report on two EGFR mutant NSCLC male patients, whose family history for breast and OC led to the detection of a gBRCA2 mutation in both cases. The authors, to investigate if genetic susceptibility to DNA repair defects could predispose to the development of EGFR mutant tumors, screened 110 Jewish patients with lung cancer and found that three harbored gBRCA mutations (2.7%). They further screened 13 Ashkenazi Jewish patients with EGFR mutant NSCLC and found that none had gBRCA1/2 mutations (8).

However, in contrast to defects caused due to a single genomic mutation, as in the case of BRCA mutations, DNA repair in LC seems to be more often affected at the epigenetic level. It has been reported that epigenetic alterations combined with reduced mRNA and protein expression levels of BRCA1 occur in up to 44% of NSCLC, through various mechanisms, such as promoter hypermethylation (7). For example, low expression of ERCC1 was shown in 56% of cases of a large cohort of NSCLC patients, whereas PTEN mutations have

| Patients number | 18 |
|-----------------|----|
| Median age at first diagnosis (years, range) | 62 (37-79) |
| Smoking habit |    |
| Never-smoker | 11 (61.1%) |
| Former-smoker | 4 (22.2%) |
| Current-smoker | 2 (11.1%) |
| Unknown | 1 (5.5%) |
| Cancer familial history |    |
| Yes | 7 (38.8%) |
| No/unknown | 11 (61.1%) |
| Synchronous LC and OC | 6 (33.3%) |
| Metachronous LC and OC | 12 (66.7%) |
| Median time interval between LC and OC diagnoses (years, range) | 4.5 (0.7-9) |
| LC histology |    |
| Adenocarcinoma | 15 (83.3%) |
| Squamous | 2 (11.1%) |
| Small cell lung cancer | 1 (5.5%) |
| OC histology |    |
| High-grade serous | 15 (83.4%) |
| Endometrioid | 1 (5.5%) |
| Mucinous | 2 (11.1%) |
| LC stage (TNM 8th edition) |    |
| I-IIa | 6 (33.3%) |
| IIIa | 6 (33.3%) |
| IIIb-IV | 4 (22.2%) |
| Unknown | 2 (11.2%) |
| OC stage (FIGO) |    |
| I | 7 (38.9%) |
| III | 7 (38.9%) |
| IV | 2 (11.1%) |
| Unknown | 2 (11.1%) |
| Median follow-up (years, range) | 6.8 (1-15) |
| Median overall survival (months, 95%CI) | 33 (1.98-55.5) |

Figure 1. Overall survival in our case-series: median overall survival was 33 months (95%CI=1.98-55.5).
been reported in 9% of NSCLC patients where they confer higher sensitivity to PARPi (7-9).

As for the implications on treatment outcome of patients with EGFR-mutant NSCLC, at least two studies showed that high BRCA1 mRNA expression was associated with shorter progression-free survival when patients received erlotinib (10-11). This evidence provided the rationale for a combination trial of the anti-EGFR TKI, gefitinib, plus the PARPi olaparib (12). This subgroup of NSCLC patients with an HR dysfunction constitutes a rare population which may
also be sensitive to treatment with PARPi. So far, it is unknown if this phenotype occurs only at the somatic level in cancer cells or, in a few cases, may also reflect a germline pattern. In our case series, whole exome sequencing was not carried out, so we can only speculate that at least in some of the cases described, the association of LC and OC was driven by an underlying common germline alteration in the DNA repair machinery.

This study has certain limitations. It is a retrospective study, with missing clinical data and limited availability of paired histological specimens. In many instances, molecular testing for LC oncogene drivers and for BRCA status in OC was not performed, in part due to the extended time frame of the study – as the recommendations for molecular testing considerably changed along the 10 years covered in this case-series – and in part for the lack of a family history suggestive for a BRCA mutation or because of the early TNM stage at the time of LC diagnosis. In this respect, it is worth to notice that many LC cases were diagnosed at early stages, probably because the lung lesions were detected as occasional radiological findings along the follow-up for the preceding OC. This could also explain the long survival time observed in this case series.

Beyond the findings and the limitations mentioned above, our report – which represents the largest patients’ series of associated LC and OC – also outlines the clinical and pathologic diagnostic challenge of distinguishing secondary from primary ovarian neoplasms. This is true especially in the presence of synchronous tumors, where imaging techniques and conventional morphology alone may be often inadequate to obtain a reliable diagnosis.

In our report, the use of appropriate IHC markers in the pathology workup revealed that, in one case, the lung lesions deemed as primary lung adenocarcinoma were actually metastases from OC. It is worth mentioning that at the time of initial diagnosis, the biopsy specimen consisted of pleural cytology, which can often be misleading.

Lung represents the second preferential metastatic site for ovarian cancer (28.4% across 819 distant metastatic sites examined from SEER database) and, when present, has negative prognostic value (13). On the other hand, ovarian metastases from LC represent only 0.4-1.0% of all ovarian metastatic masses (14-16). However, such frequency is likely to increase due to the rising incidence of lung cancer in women (1). Surprisingly, several reports have described cases of ovarian metastases from lung adenocarcinoma associated with driver EGFR mutations, and even more commonly, with ALK rearrangements (17).

In conclusion, our study represents the largest case series of double LC and OC primaries, that not only underlines the key role of IHC in the differential diagnosis of metastatic disease, but also identifies common clinical and pathological features, with many cases driven by genetic alterations. As a future perspective, further analyses using an NGS panel could shed light on the biological mechanisms driving the occurrence of concomitant LC and OC, with beneficial repercussions on prevention and treatment strategies.

Conflicts of Interest

Mariniello A received financial support for travel and accommodation to participate to scientific events by Roche and Bristol Myers Squibb; Chiari R received speaker’s fees from AstraZeneca, Roche, Takeda, Boheringer Ingelheim, Otsuka, Pfizer; Di Conte A received speaker’s fees from AstraZeneca, BMS, Merck Sharp & Dome, Roche; Di Maio M received personal fees from Bristol Myers Squibb, Merck Sharp & Dome, Roche, AstraZeneca, Janssen, Takeda, Pfizer and institutional research grant from Tesaro; Valabrega G received speaker’s fees from AstraZeneca, Roche, PharmaMar, Tesaro; Novello S declares Speaker Bureau and/or Advisor for BMS, Eli Lilly, BI, Astra Zeneca, MSD, Takeda, Roche; Ghisoni E, Righi L, Gelibter A, Zichi C, Catino A, Barbieri F, Grij Levara M and Cecere F declare no conflicts of interest.

Authors’ Contributions

Conception and design: Novello S and Valabrega G. Acquisition of data: Mariniello A. Pathology revision and images of figures 2 and 3: Righi L. Analysis and interpretation of data: Mariniello A, Ghisoni E. Drafting the article: Mariniello A. Critically revising the article for important intellectual content: Novello S, Valabrega G, Righi L, Di Maio M. All Authors read and approved the final manuscript.

Acknowledgements

The Authors would like to acknowledge all the patients and their families that participated in this study by providing clinical data and biopsy tissues. The Authors also thank the data managers of the single Institutions that helped to collect tissue specimens for the pathology revision.

References

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
2 Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4): 284-296, 2018. PMID: 29809280. DOI: 10.3322/caac.21456
3 Vavalà T, Mariniello A, Reale ML and Novello S: Gender differences in lung cancer. Ital J Gender-Specific Med 2(3): 99- 109, 2016.
4 Remon J, Isla D, Garrido P, de Castro I, Majem M, Viñolas N, Artal A, Carcereny E, García-Cam peno MR, Llanes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C and Felip E: Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Clin Transl Oncol 19(12): 1537-1542, 2017. PMID: 28660482. DOI: 10.1007/s12094-017-1700-8
5 Lord CJ and Ashworth A: BRCAness revisited. Nat Rev Cancer 16(2): 110-120, 2016. PMID: 26775620. DOI: 10.1038/nrc.2015.21
6 Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474(7353): 609-615, 2011. PMID: 21720365. DOI: 10.1038/nature10166
7 O'Sullivan CC, Moon DH, Kohn EC and Lee JM: Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 4: 42, 2014. PMID: 24616882. DOI: 10.3389/fonc.2014.00042
8 Marks JL, Golas B, Kirchoff T, Miller VA, Riely GJ, Offit K and Pao W: EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. J Thorac Oncol 3(7): 805, 2018. PMID: 18594331. DOI: 10.1097/JTO.0b013e3181e4664
9 Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC and IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991, 2006. PMID: 16957145.
10 Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provenicio M, Cobo M, Insua A, Garcia-Camprolo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL and Taron M: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17(5): 1160-1168, 2011. PMID: 2133402. DOI: 10.1158/1078-0432.CCR-10-2158
11 Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R and Spanish Lung Cancer Group: BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol 8(3): 295-300, 2013. PMID: 23407556. DOI: 10.1097/JTO.0b013e31827db621
12 Campeolo RG, Felip E, Massuti B, Majem M, Carcereny E, Cardenal F, Molina-Vila MA, Martinez Marti A, Marti-Ciriciqu JL, Alonso-Jaudenes Curbera G, Pallares C, Palmero R, Gonzalez-Arenas MC, Mayo-de las Casas C, Sanchez-Ronco M and Rosell R: Phase IIb study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell-lung cancer (NSCLC) (NCT 01513174/GECP: GOAL). J Clin Oncol 31: abstr2581, 2013. DOI: 10.1200/jco.2013.31.15_suppl.2581
13 Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, Lou G, Li Z, Li K and Hou Y: Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol 150(3): 460-465, 2018. PMID: 30001833. DOI: 10.1016/j.ygyno.2018.06.022
14 Fujiwara K, Ohishi Y, Koike H, Sawada S, Moriya T and Kohno I: Clinical implications of metastases to the ovary. Gynecol Oncol 59(1): 124-128, 1995. PMID: 7557597. DOI: 10.1006/jgyn.1995.1278
15 Kiyokawa T, Young RH and Scully RE: Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30(3): 277-299, 2006. PMID:16538048. DOI: 10.1097/01.pas.0000190787.85024.cb
16 Irving JA and Young RH: Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis. Am J Surg Pathol 29(8): 997-1006, 2005. PMID: 16006793.
17 Sasano H, Sekine A, Hirata T, Iwamoto K, Itou Y, Itani H, Kondou S, Tokui T and Tanigawa M: Ovarian metastases from ALK-rearranged lung adenocarcinoma: A case report and literature review. Intern Med 57(22): 3271-3275, 2018. PMID: 29984766. DOI: 10.2169/internalmedicine.0538-17

Received July 15, 2019
Revised July 22, 2019
Accepted July 23, 2019